CYTOGENETIC EVALUATION OF THE MECHANISM OF CELL-DEATH INDUCED BY THE NOVEL ANTHRACENYL-AMINO ACID TOPOISOMERASE-II CATALYTIC INHIBITOR NU/ICRF-500

被引：12

作者：

CUMMINGS, J ^{[1
]}

SUMNER, AT ^{[1
]}

SLAVOTINEK, A ^{[1
]}

MEIKLE, I ^{[1
]}

MACPHERSON, JS ^{[1
]}

SMYTH, JF ^{[1
]}

机构：

[1] WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND

来源：

MUTATION RESEARCH-GENETIC TOXICOLOGY | 1995年 / 344卷 / 1-2期

关键词：

ANTHRACENYL AMINO ACID DIPEPTIDE CONJUGATE; TOPOISOMERASE I; TOPOISOMERASE II; CHROMOSOMAL DAMAGE; CHROMOSOME SEGREGATION; CELL CYCLE ANALYSIS;

D O I：

10.1016/0165-1218(95)90038-1

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Anthracenyl-amino acid/dipeptides are novel topoisomerase (topo) inhibitors which can be actively cytotoxic in the low mu M range. The present studies have been performed to determine whether cells treated with the topo II catalytic inhibitor NU/ICRF 500 (serine derivative) would manifest cytogenetic lesions consistent with its proposed mechanism of enzyme inhibition. Three other compounds were included for comparison: NU/ICRF 505 (tyrosine) which stabilises topo I cleavable complexes, NU/ICRF 602 (gly-gly) a non-cytotoxic catalytic inhibitor of topo I and II and NU/ICRF 502 (alanine) a non-cytotoxic non-topo inhibitor. Chromosomal damage was measured using the micronucleus test, NU/ICRF 500 (7.5-30 mu M) induced an increase in CREST negative micronuclei (11-15 per 500 cells) in human lymphocytes (HL) and blocked the traverse of HL through the cell cycle, with cells accumulating in G2/M at 15 mu M drug and G1/S at 30 mu M drug. NU/ICRF 502 was without effect in the micronucleus test. NTJ/ICRF 500 and 602 (90-150 mu M) caused no block in passage of synchronised metaphase Chinese hamster ovary cells through mitosis whereas NU/ICRF 505 produced a significant delay. DNA measurements of post-mitotic cells revealed that after NU/ICRF 500 treatment nuclei had a 4C DNA content, indicative of a lack of chromosomal segregation. Normal (2C) DNA content was observed with NU/ICRF 505 and 602. Overall, the data for NU/ICRF 500 are consistent with the cytogenetic modifications expected after catalytic inhibition of topo II and suggest that cell death may be mediated, at least in part, through this mechanism.

引用

页码：55 / 62

页数：8

共 33 条

[1]

ANDOH T, 1993, BIOTECHNOL APPL BIOC, V18, P165

[2] NOVEL ACTIONS OF INHIBITORS OF DNA TOPOISOMERASE-II IN DRUG-RESISTANT TUMOR-CELLS [J].

BECK, WT ;

KIM, R ;

CHEN, M .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 :S14-S18

[3] INSITU LOCALIZATION OF DNA TOPOISOMERASE-II, A MAJOR POLYPEPTIDE COMPONENT OF THE DROSOPHILA NUCLEAR MATRIX-FRACTION [J].

BERRIOS, M ;

OSHEROFF, N ;

FISHER, PA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (12) :4142-4146

[4] INHIBITION OF TYPE-II TOPOISOMERASE BY FOSTRIECIN [J].

BORITZKI, TJ ;

WOLFARD, TS ;

BESSERER, JA ;

JACKSON, RC ;

FRY, DW .

BIOCHEMICAL PHARMACOLOGY, 1988, 37 (21) :4063-4068

[5] DNA TOPOISOMERASES - ESSENTIAL ENZYMES AND LETHAL TARGETS [J].

CHEN, AY ;

LIU, LF .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1994, 34 :191-218

[6]

CHEN M, 1993, CANCER RES, V53, P5946

[7] CHROMOSOMAL LOOP ANCHORAGE OF THE KAPPA IMMUNOGLOBULIN GENE OCCURS NEXT TO THE ENHANCER IN A REGION CONTAINING TOPOISOMERASE-II SITES [J].

COCKERILL, PN ;

GARRARD, WT .

CELL, 1986, 44 (02) :273-282

[8]

CORBETT AH, 1993, CHEM RES TOXICOL, V6, P586

[9] SYNERGISTIC EFFECT OF INHIBITORS OF TOPOISOMERASE-I AND TOPOISOMERASE-II ON CHROMOSOME-DAMAGE AND CELL-KILLING IN CULTURED CHINESE-HAMSTER OVARY CELLS [J].

CORTES, F ;

PINERO, J .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 (05) :411-415

[10] DNA TOPOISOMERASE-1 AND TOPOISOMERASE-2 AS TARGETS FOR RATIONAL DESIGN OF NEW ANTICANCER DRUGS [J].

CUMMINGS, J ;

SMYTH, JF .

ANNALS OF ONCOLOGY, 1993, 4 (07) :533-543

← 1 2 3 4 →